Academic Reading — Test 92

Reading passage

Snakebite envenoming remains one of the most neglected public health problems in the rural tropics, and nowhere is its burden heavier than in India. Each year the country records tens of thousands of deaths from venomous bites, a figure widely believed to be an underestimate because many incidents occur in remote villages and are never reported to formal health centres. The majority of these fatalities are attributed to a small group of species known collectively as the "big four": the spectacled cobra, the common krait, Russell's viper and the saw-scaled viper. These snakes thrive in the agricultural landscapes where most Indians live and work, so farmers and labourers who walk barefoot through fields at dusk are especially vulnerable. The economic consequences extend well beyond the immediate medical emergency, as survivors may be left with permanent tissue damage, amputations or an inability to return to physical labour. The clinical effects of envenoming vary considerably according to the type of venom involved. The venom of cobras and kraits is predominantly neurotoxic, meaning that it disrupts the signals passing between nerves and muscles; victims may experience drooping eyelids, difficulty swallowing and, in severe cases, paralysis of the muscles that control breathing. By contrast, the venom of vipers tends to be haemotoxic, attacking the blood and tissues so that bleeding, swelling and clotting disorders predominate. Because the symptoms can be delayed by several hours, a bite that initially seems trivial may prove deadly, and prompt treatment is therefore essential. The only specific remedy widely available is antivenom, a preparation of antibodies capable of neutralising the toxic proteins circulating in the patient's bloodstream. The principle behind antivenom has changed remarkably little since it was first developed in the late nineteenth century. To manufacture it, small and carefully controlled doses of venom are injected into a large mammal over a period of several months. The animal's immune system responds by producing antibodies against the venom, and these antibodies accumulate in its blood. Blood is then drawn from the animal, the red cells are separated and returned, and the antibody-rich plasma is processed to extract and purify the protective proteins. In India, the horse has traditionally been the animal of choice for this purpose, chiefly because its large body size allows substantial volumes of blood to be collected without harming the donor. Herds of horses are maintained at specialised facilities where their health is monitored closely and their immunity is gradually built up. Despite its long history of success, the horse-based method has well-recognised drawbacks. Horse antibodies are foreign proteins, and a proportion of patients react badly to them, suffering allergic responses that range from mild rashes to a dangerous whole-body reaction known as anaphylaxis. Some patients also develop a delayed illness, called serum sickness, several days after treatment. For this reason researchers have explored alternative sources of antibodies, and sheep have attracted particular interest. Antibodies raised in sheep can be processed using a technique that cuts the antibody molecule and keeps only the fragment that binds the venom, discarding the portion most likely to provoke an immune reaction. Supporters argue that such purified fragments are cleaner and may be tolerated better, although sheep yield less blood than horses and the resulting product is more expensive to make. A further and often overlooked limitation is geographical. The venom of a single species can differ from one region to another, so an antivenom raised against snakes from one part of India may work poorly against the same species elsewhere. Most Indian antivenom has historically been produced using venom collected from snakes in a single southern area, which means it can be less effective in the north or east of the country. Scientists now advocate the preparation of region-specific products, manufactured from venom gathered across the whole range of each species, to ensure that the antibodies match the toxins a patient is actually likely to encounter. Improving the cold chain that keeps the product stable, training rural clinicians to administer it correctly, and persuading communities to seek hospital care rather than traditional healers are regarded as equally important steps. Antivenom alone, however well designed, cannot reduce the toll unless it reaches the bedside in time.